Combination Therapy Boosts Durability of CAR T-Cell Response in Hematologic Cancers

In hematologic malignancies, chimeric antigen receptor (CAR)-modified T cells will be increasingly combined with ...

JANUARY 10, 2019

Large Study Confirms DAAs Protect Against HCC When SVR Achieved

Patients with HCV who are successfully treated with direct-acting antiviral agents experience a dramatic reduction ...

APRIL 4, 2018

Are Adverse Effects Underreported?

Copenhagen, Denmark—Side effect management is one of the more important tasks specialty pharmacists need to ...

FEBRUARY 22, 2017

Immunotherapies Being Tested Earlier in NSCLC

In the front-line treatment of NSCLC, the checkpoint inhibitor pembrolizumab improved progression-free survival ...

DECEMBER 16, 2016

Taming HCV in Challenging Populations

San Diego—Virtually all patients infected with hepatitis C virus (HCV) have a high likelihood of achieving a ...

OCTOBER 10, 2016

Adjuvant LMWH Fails to Improve Survival in NSCLC

When combined with chemotherapy as an adjuvant therapy after resection for non-small cell lung cancer, ...

SEPTEMBER 20, 2016

Durable Responses With CAR T Cells in B-Cell ALL

Chicago—This investigative agent is destined for widespread use in refractory B-cell leukemias and lymphomas. ...

SEPTEMBER 7, 2016

New Hep C Recs Target Unique Populations

Updated HCV guidelines focus on cirrhosis, other challenging patients.

MAY 12, 2016